ALZA Corp. will expand its U.S. sales force from fewer than 100 to a total of approximately 360 sales representatives, the Palo Alto, CA-based company announced in July.
ALZA Corp. will expand its U.S. sales force from fewer than 100 to a total of approximately 360 sales representatives, the Palo Alto, CA-based company announced in July.
"We are adding significant strength to our sales organization in both urology and oncology because we believe our existing portfolio, as well as products under late development, such as Ditropan® XL and DUROS⢠leuprolide, will benefit greatly from increased exposure to prescribing physicians," said Ernest Mario, the company's chairman and CEO.
The bigger sales force will be divided into two specialty groups. One will be focused exclusively on the promotion of oncology products to oncologists and the other will be dedicated to promoting urology products to urologists and high-prescribing primary care physicians.
The bulk of the new hires will promote ALZA's urology product line, which includes Elmiron® (pentosan polysulfate), Ditropan® (oxybutynin chloride) and Testoderm® TTS (Testosterone Transdermal System). They will also promote Ditropan® XL, if the FDA grants the product in development marketing clearance.
Seventy-five of the new urology hires will come from Menlo Park, CA-based VIVUS Inc., which markets Muse® (alprostadil) for erectile dysfunction, ALZA reported.
The former VIVUS sales reps will continue to promote Muse for VIVUS until the end of 1998 before focusing solely on ALZA products, according to the agreement between the two companies.
Under a separate agreement, ALZA will also hire 150 contract sales reps from Yardsley, PA-based Innovex Inc. to detail urology products to primary care physicians. PR
The Weight-Loss Gold Rush: Legal and Regulatory Implications
July 11th 2024Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses how the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs, what needs to be done for GLP-1s to be covered, advice for investors and financiers considering entering the weight-loss medication market and more.
Healthcare Marketing Strategies for Reaching Diverse Audiences
May 14th 2024Amanda Powers-Han, Chief Marketing Officer, Greater Than One, and Pharmaceutical Executive Editorial Advisory Board member, discusses how improved DE&I in healthcare marketing strategies can not only reach diverse audiences more effectively but also contribute to improved patient care outcomes, challenges faced in crafting culturally sensitive messages, and much more.